The Kidpreneur Club helps young, future business owners
TAMPA, Fla. (WFLA) — At just 9-years old, Elliott Perez is already quite the businessman. He says it feels amazing when he makes a sale.
Perez started his business, Fluff, Puffs and Other Stuff, under the Kidpreneur program, where he makes and sells crafts like pillows and fun artwork.
He's one of over a hundred kids who are part of the non-profit.
Executive Director of The Kidpreneur Club, Danielle Cannon calls the program, 'a lemonade stand on steroids.'
Cannon started The Kidpreneur Club after she realized there was a gap in the community for kids who wanted to sell their own crafts somewhere other than the end of their driveway. Through the non-profit, kids and teenagers take their business to local markets where they learn everything from pricing their items, to customer service, which can be intimidating!
'They've really come out of their shells,' says Cannon. 'By their third fair they'll be yelling, 'Over here! I've got this for sale!''
Teaghan Cullen started her jewelry and keychain-making business when she says she was looking for something to do during COVID. She says she's learned a lot so far.
'Before, I didn't know how to price things right so I was taught to count up how much your supplies cost so you have the right price,' says Cullen.
Lilienne Spurgeon is in 8th grade and makes glass sculptures, ornaments and ornate jewelry out of copper.
The markets are an especially helpful learning tool for her when it comes to sales.
'Be a little more confident, be a little more open. That's what I've learned about that, as well as budgeting what you put in and what you get out of it,' says Spurgeon.
All three of these kidpreneurs say they hope to one day be successful business owners. It's safe to say they are well on their way.
If you'd like to donate to help provide scholarships for kids who attend classes and to learn more about the non-profit, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
30 minutes ago
- Associated Press
SOHM Inc. Welcomes Dr. Lucia Piccotti to Offer Expert Guidance on Cosmeceutical and Personal Health Product Research and Development
CHINO HILLS, CA / ACCESS Newswire / June 4, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, health and wellness solutions, proudly announces the appointment of Dr. Lucia Piccotti, PhD, EMBA, as a key member of our team. Dr. Piccotti will serve on the advisory board, advising on the development of cutting-edge cosmeceuticals and personal health products utilizing SOHM's cutting-edge technological advancements. Dr. Piccotti is a distinguished biomedical scientist and strategic business leader, bringing over a decade of expertise in blending scientific research with entrepreneurial innovation. Her career has taken her through pivotal roles in both Fortune 500 companies and dynamic biotech startups, where she has excelled in translating complex biomedical concepts into impactful consumer products and business strategies. Most recently, Dr. Piccotti served as Senior Director of Strategic Innovation at Kiromic Biopharma, a biotechnology company at the forefront of cell therapies for cancer. Her contributions were instrumental in navigating the company's growth through the critical phases of pre-IPO and post-IPO operations. Notably, she led innovative initiatives that utilized exosome technologies for skin health, showcasing her extensive knowledge and versatility in both therapeutic and consumer health applications. In addition to her role at Kiromic, Dr. Piccotti is the founder of Iguvia LLC, a consulting firm that specializes in cosmeceuticals and health products. Since 2018, she has directed multiple projects focused on phytoextract-based topical applications, drawing on her in-depth expertise in skin health and bioactive formulation. Earlier in her career, Dr. Piccotti was a Lead Scientist at Kimberly-Clark Corporation, where she advanced biomedical research and product development in the personal care and cosmeceutical sectors. Her innovative work has resulted in numerous patents and industry-recognized advancements, particularly in the use of phytoextracts and topical formulations. Dr. Piccotti's impressive track record includes managing cross-functional teams and complex research studies, as well as collaborating with various departments, including Marketing and Regulatory Affairs. Her extensive network within the medical community, including connections with top institutions like the University of Texas and MD Anderson Cancer Center, positions her uniquely to drive SOHM Inc.'s growth and innovation in the industry. 'With Dr. Piccotti on board, we are poised to elevate our approach to cosmeceuticals and personal health products,' said David Aguilar, COO of SOHM Inc. 'Her strategic thinking and innovative mindset will significantly enhance our capabilities and ensure we continue to deliver high-quality solutions that meet the evolving needs of consumers.' Dr. Piccotti graduated with a PhD in Biochemistry, where her thesis focused on liposomal delivery of anionic phospholipids to support mitochondrial bioenergetics, with implications for cellular aging. She also holds an MS in Chemistry with a thesis in Synthetic Organic Chemistry, and an Executive MBA, demonstrating her commitment to both scientific excellence and business leadership. Her collaborative leadership style and entrepreneurial spirit will be invaluable as she helps SOHM navigate the complexities of the cosmeceutical market. About SOHM, Inc.: SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted solutions for gene editing. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery. For further information regarding this announcement or to explore potential collaborations, please contact: SOHM, Inc.: Name: Baron Night, CEO/Dr. David Aguilar, COO Email: [email protected] Phone: (714) 522-6700 Safe Harbor Statement: This news release contains 'forward-looking statements,' which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on SOURCE: SOHM, Inc press release
Business Wire
an hour ago
- Business Wire
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced that members of its executive leadership team will be attending and participating in the upcoming BIO International Convention 2025, taking place June 16-19, 2025 in Boston. Cadrenal executives will participate in one-on-one meetings with investors and potential partners to provide key updates on the Company's strategic direction and clinical development of its lead asset, tecarfarin. Those interested in meeting with Cadrenal management should request a meeting through the Conference meeting portal or contact Investor Relations at cadrenal@ The BIO International Convention is the world's largest and most comprehensive biotechnology event, convening over 20,000 industry leaders from across the global life sciences ecosystem. About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease. Cadrenal's lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for a number of indications, extensive clinical and real-world data have shown it can have significant, serious side effects. With tecarfarin, Cadrenal is advancing an innovative solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of warfarin and capture value in a market with high demand for safer, more manageable treatment options. Cadrenal is pursuing a pipeline-in-a-product approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit and connect with us on LinkedIn.
Associated Press
an hour ago
- Associated Press
ELV LAWSUIT NOTICE: Lose Money on Elevance Health, Inc.? BFA Law Alerts Investors that the Class Action Could Allow Investors to Recover Losses (NYSE:ELV)
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting Investors have until July 11, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Elevance common stock. The case is pending in the U.S. District Court for the Southern District of Indiana and is captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092. Why was Elevance Sued for Securities Fraud? Elevance provides health insurance plans. This includes contracting with states to administer Medicaid benefits. States routinely review Medicaid eligibility, but during COVID, the federal government paused this process. The pause ended in 2023, and states resumed redetermining Medicaid eligibility. During the relevant period, Elevance represented that it was closely monitoring the cost trends associated with the redetermination process and that the rates Elevance was negotiating were sufficient to address the risk profiles of those patients staying on Medicaid. As alleged, in truth, the redeterminations caused a significant increase in the acuity and utilization of Elevance's Medicaid members. What's more, the shift occurred to a degree that was not reflected in Elevance's rate negotiations or in its financial guidance for 2024. The Stock Declines as the Truth is Revealed On July 17, 2024, Elevance stated that it was now 'expecting second-half utilization to increase in Medicaid' and that it was 'seeing signs of increased utilization across the broader Medicaid population.' On this news, the price of Elevance stock declined $32.21 per share, or nearly 6%, from $553.14 per share on July 16, 2024, to $520.93 per share on July 17, 2024. Then, on October 17, 2024, Elevance announced its Q3 2024 financial results, revealing that its missed consensus earnings per share ('EPS') expectations by $1.33, or 13.7%, 'due to elevated medical costs in [its] Medicaid business.' On this news, the price of Elevance stock declined $52.61 per share, or nearly 11%, from $496.96 per share on October 16, 2024, to $444.35 per share on October 17, 2024. Click here if you suffered losses: What Can You Do? If you invested in Elevance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212-789-3619 Why Bleichmar Fonti & Auld LLP? Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
